Haemonetics (NYSE:HAE) Stock Price Target Raised at Citigroup

Haemonetics (NYSE:HAE) had its target price boosted by Citigroup from $123.00 to $149.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Several other equities research analysts have also recently issued reports on the stock. Raymond James Financial lifted their target price on shares of Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, September 3rd. Wall Street Zen upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. raised their price target on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. BTIG Research boosted their price target on shares of Haemonetics from $130.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Barrington Research boosted their price target on shares of Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.38.

Haemonetics Price Performance

HAE stock traded down $4.24 during trading on Friday, hitting $119.87. The stock had a trading volume of 834,665 shares, compared to its average volume of 762,819. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. Haemonetics has a twelve month low of $51.00 and a twelve month high of $132.00. The stock has a market capitalization of $5.45 billion, a P/E ratio of 53.75, a PEG ratio of 2.40 and a beta of 0.63. The company’s 50-day moving average price is $111.48 and its two-hundred day moving average price is $80.05.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, topping the consensus estimate of $1.29 by $0.06. The company had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. Haemonetics’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.27 EPS. As a group, research analysts predict that Haemonetics will post 5.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HAE. Dimensional Fund Advisors LP increased its stake in shares of Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Haemonetics by 1,191.9% in the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after purchasing an additional 418,470 shares during the period. Bank of America Corp DE acquired a new stake in Haemonetics during the second quarter worth about $33,326,000. London Co. of Virginia increased its position in Haemonetics by 33.9% during the first quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock worth $19,884,000 after purchasing an additional 89,242 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new position in Haemonetics during the second quarter worth about $24,906,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
• Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
• Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
• Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.